B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) [Phase 2]
Phase 2 trial update evaluating a second, early reinfusion of tisagenlecleucel in children and young adults with B-cell acute lymphoblastic …
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma [Phase 1]
Phase 1 trial evaluating an in vivo CAR-T therapy targeting CD19 and BAFF-R for relapsed/refractory B-cell acute lymphoblastic leukemia and …
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 1]
Phase 1 dose-escalation and dose-expansion study to evaluate the safety of Azer-cel (PBCAR0191) in relapsed/refractory non-Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Venetoclax Plus Inotuzumab for B-ALL [Phase 1]
This is an update on a Phase 1 trial of venetoclax plus inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia and B-cell lymphoma; t…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating low-intensity chemotherapy plus venetoclax for relapsed or refractory B-cell and T-cell acute lymph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors [EARLY_Phase 1]
This is an early-phase clinical trial update for LV009 injection evaluating its use in CD19-positive recurrent/refractory B-cell acute lymph…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL [EARLY_Phase 1]
An early-phase Phase 1 study of a novel TLR2-containing CAR-T cell therapy targeting CD19 and CD22 for relapsed/refractory B-cell acute lymp…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) [EARLY_Phase 1]
An early Phase 1 clinical trial of JY231 injection for B-cell acute lymphoblastic leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) [Phase 1, Phase 2]
A phase 1/2 pediatric trial is evaluating autologous HuCART19 T cells produced with the CliniMACS Prodigy platform for B-cell acute lymphobl…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 clinical trial evaluating humanized CD19-specific CAR T cells for relapsed or refractory CD19-positive B-cell acute lymphoblastic le…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) [Phase 1]
Phase 1 study of a CD70-targeted chimeric antigen receptor (CAR) T-cell therapy named SEVENTY for acute leukemias; the trial is not yet recr…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: Autologous Bedside CD19 CAR T-cell Therapy for B-ALL [EARLY_Phase 1]
An early-phase trial of autologous bedside CD19 CAR T-cell therapy for adult B-cell acute lymphoblastic leukemia is underway. The study is c…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
This document provides a real-world study update evaluating CNCT-19 CAR-T therapy for adults with B-cell acute lymphoblastic leukemia.
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 clinical trial evaluating cellular immunotherapy for high-risk B-cell acute lymphoblastic leukemia, with status listed as active but…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia [Phase 1]
This clinical trial update reports on a Phase 1 study of a CD19-CD22 bispecific CAR-T cell therapy for pediatric acute lymphoblastic leukemi…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL [Phase 1]
Phase 1 clinical trial evaluating allogeneic second-generation CD19-CAR T cells for pediatric relapsed/refractory B-cell acute lymphoblastic…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Allogeneic UCB-derived CAR-T for B-ALL [EARLY_Phase 1]
Clinical trial update on an allogeneic umbilical cord blood–derived CAR-T therapy for B-cell acute lymphoblastic leukemia in early Phase 1, …
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL [Phase 1]
A Phase 1 clinical trial assessing a CD19x22 CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia [Phase 1]
This clinical trial update describes Phase 1 testing of KSV01 Injection for relapsed/refractory B-cell acute lymphoblastic leukemia. Recruit…
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL [Phase 2]
A Phase 2 clinical trial is assessing Senl_B19 CAR-T cells for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia and is currentl…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies [Phase 1]
A Phase 1 clinical trial of an in vivo CAR-T therapy for relapsed/refractory hematologic cancers is currently recruiting. The study targets …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms [Phase 1]
Phase 1 study of CT1195E in relapsed/refractory B-cell neoplasms is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies [Phase 1]
A Phase 1 study from Stanford is evaluating CD19/CD22 CAR T cells with or without NKTR-255 in adults with recurrent or refractory B-cell mal…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) [Phase 1]
Phase 1 trial update of CAR T cells (CARPASCIO) targeting CD19 in relapsed CD19+ malignancies after allogeneic HSCT. The study is currently …
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
This clinical trial update reports on long-term follow-up, quality of life outcomes, and adverse reactions for CAR T-cell therapy in B-cell …